Stocktoria
MIRA PHARMACEUTICALS, INC. MIRA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2023-08-03
MIRA PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $1.7M | $3.3M | $1.6M | $2.4M |
| Interest expense | — | -$165,669 | $3.5M | $10,250 |
| Net income | -$10.4M | -$7.9M | -$12.0M | -$7.1M |
| EPS (diluted) | $-1.35 | $-0.51 | $-0.85 | $-0.40 |
| Operating cash flow | -$4.7M | -$5.6M | -$4.5M | -$5.6M |
| Cash & equivalents | $6.3M | $2.8M | — | — |
| Total assets | $11.1M | $2.9M | $4.9M | $858,074 |
| Total liabilities | $702,068 | $723,349 | $558,097 | $1.5M |
| Shareholders' equity | $10.4M | $2.2M | $4.4M | -$596,232 |
Source: SEC EDGAR filings · CIK 0001904286 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.